These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 27615536)

  • 1. Understanding immunotherapy for the treatment of non-small cell lung cancer.
    Thomas R
    Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
    N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab: a review in advanced squamous non-small cell lung cancer.
    Keating GM
    Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.
    Rounds A; Kolesar J
    Am J Health Syst Pharm; 2015 Nov; 72(21):1851-5. PubMed ID: 26490818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Moro-Sibilot D; Ferrer L; Levra MG; Toffart AC
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S12-5. PubMed ID: 27494968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
    Lim JS; Soo RA
    Ther Adv Respir Dis; 2016 Oct; 10(5):444-54. PubMed ID: 27480166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best practice in the treatment of advanced squamous cell lung cancer.
    Ang YL; Tan HL; Soo RA
    Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.
    Kazandjian D; Khozin S; Blumenthal G; Zhang L; Tang S; Libeg M; Kluetz P; Sridhara R; Keegan P; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):118-22. PubMed ID: 26470053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
    Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
    Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
    [No Abstract]   [Full Text] [Related]  

  • 11. Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.
    Kaneda T; Kurata T; Yoshida T; Kibata K; Yoshioka H; Yanagimoto H; Takeda K; Yoshida T; Tsuta K
    BMC Cancer; 2022 Feb; 22(1):154. PubMed ID: 35135489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
    Yang YJ; Park JC; Kim HK; Kang JH; Park SY
    Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
    Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
    Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
    Tanvetyanon T; Creelan BC; Antonia SJ
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
    Ettinger DS; Wood DE; Akerley W; Bazhenova LA; Borghaei H; Camidge DR; Cheney RT; Chirieac LR; D'Amico TA; Dilling TJ; Dobelbower MC; Govindan R; Hennon M; Horn L; Jahan TM; Komaki R; Lackner RP; Lanuti M; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel JD; Pisters KM; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Sharma N; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
    J Natl Compr Canc Netw; 2016 Mar; 14(3):255-64. PubMed ID: 26957612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for non-small cell lung cancer.
    Vafadar S
    JAAPA; 2019 Sep; 32(9):37-42. PubMed ID: 31460972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
    Decatris MP; O'Byrne KJ
    Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Keating GM
    Drugs; 2016 Jun; 76(9):969-78. PubMed ID: 27189706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.